

References

I-234

1. Kushner BH, Cheung IY, Modak S, et al. Humanized 3F8 Anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma a phase I clinical trial. *JAMA Oncol.* 2018;4(12):1729-1935.
2. Sujjitjoo J, Sayour E, Tsao ST, et al. GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma- assessing tumor and T cell interaction. *Translational Oncology.* 2021;1-11.
3. National Comprehensive Cancer Network (NCCN). Drug Name. *NCCN Drugs and Biologics Compendium®.* 2021.
4. Danyelza® (naxitamab), for intravenous use [package insert]. Y-mAbs Therapeutics, Inc. New York, NY. Revised 11/2020.
5. *Clinical Pharmacology™ Compendium.* 2021. Tampa FL: Gold Standard, Inc. Naxitamab.
6. *Micromedex DrugDex Compendium®.* 2021. Naxitamab.
7. [Naxitamab] In: *AHFS Drug Information Online Electronic Medical Library.* Bethesda, MD: American Society of Health-System Pharmacists. Updated 2021.
8. Naxitamab. *Lexi-Drugs.* Hudson, OH: Lexicomp, 2021.
9. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.